Brief: Gensight Biologics Announces The Re-Approval Of Its Full Year 2022 Consolidated Financial Statements
01/05/2023 17:36
Gensight Biologics SA SIGHT.PA :
* GENSIGHT BIOLOGICS ANNOUNCES THE RE-APPROVAL OF ITS FULL
YEAR
2022 CONSOLIDATED FINANCIAL STATEMENTS
Source text for Eikon: ID:nBw1JpnSBa
Further company coverage: SIGHT.PA
Recent news on Gensight Biologics SA
See all newsHealth Rounds: Blindness treatment based on Nobel-winning research shows promise
France's GenSight Biologics H1 net loss widens on higher R&D expenses
Brief: GenSight Biologics H1 Net Income EUR -10.3 Million
France's GenSight Biologics 2025 net loss narrows on reduced R&D spending
Brief: GenSight Biologics FY EPS EUR -0.08